Luye Pharma Group Limited operates in the Medicinals and botanicals sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Luye Pharma Group Limited with three other
pharmaceutical manufacturers in Asia:
Shanxi Zhendong Pharmaceutical Co Ltd
sales of 3.73 billion Chinese Renmimbi [US$544.22 million]
of which 101%
was Medicine Manufacture and Sale),
ChangChun High New Technology Industries
(4.04 billion Chinese Renmimbi [US$589.11 million]
of which 85%
was Medication), and
JW Holdings Corporation
based in South Korea
(683.72 billion Korean Won [US$613.98 million]
of which 110%
Luye Pharma Group Limited reported sales of 777.88 million Singapore Dollars (US$569.05 million)
December of 2017.
increase of 28.4%
versus 2016, when the company's sales were 605.73 million Singapore Dollars.
Sales of Alimentary Tract and Metabolism Drugs saw an increase
32.7% in 2017, from
115.11 million Singapore Dollars to 152.78 million Singapore Dollars.
Not all segments of Luye Pharma Group Limited experienced an increase in sales in 2017:
sales of Other fell 4.7% to 27.98 million Singapore Dollars.
(However, this segment's sales were only a very small portion of the company's overall sales).
Luye Pharma Group Limited also experienced decreases in sales in
Cardio-Vascular System Drugs (down 3.0% to 131.32 million Singapore Dollars)